Ars.els-cdn.com



Supplementary Table 1. Prevalence estimates of selected disease states in the DoD and US populations. ADDIN EN.CITE <EndNote><Cite><Author>Dorrance</Author><Year>2013</Year><RecNum>51</RecNum><DisplayText>(Dorrance, Ramchandani, 2013)</DisplayText><record><rec-number>51</rec-number><foreign-keys><key app="EN" db-id="dxa9p0dzrxszx0epfaw52s5j29pffrf9e20s">51</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Dorrance, K. A.</author><author>Ramchandani, S.</author><author>Neil, N.</author><author>Fisher, H.</author></authors></contributors><auth-address>Walter Reed National Military Medical Center, 8901 Wisconsin Avenue, Bethesda, MD 20889, USA.</auth-address><titles><title>Leveraging the military health system as a laboratory for health care reform</title><secondary-title>Mil Med</secondary-title></titles><pages>142–5</pages><volume>178</volume><number>2</number><edition>2013/03/19</edition><keywords><keyword>Adolescent</keyword><keyword>Adult</keyword><keyword>Aged</keyword><keyword>Budgets</keyword><keyword>Child</keyword><keyword>Comparative Effectiveness Research</keyword><keyword>Delivery of Health Care/organization &amp; administration</keyword><keyword>Female</keyword><keyword>Health Care Reform/*organization &amp; administration</keyword><keyword>Humans</keyword><keyword>Male</keyword><keyword>Middle Aged</keyword><keyword>Military Medicine/economics/*organization &amp; administration</keyword><keyword>Models, Organizational</keyword><keyword>Private Sector/organization &amp; administration</keyword><keyword>United States</keyword><keyword>Young Adult</keyword></keywords><dates><year>2013</year><pub-dates><date>Feb</date></pub-dates></dates><isbn>0026-4075 (Print)&#xD;0026-4075 (Linking)</isbn><accession-num>23495458</accession-num><urls><related-urls><url>;(Dorrance, Ramchandani, 2013)Disease stateDoD population prevalence per 100,000population (year) US population prevalence per 100,000population (year)Ischemic heart disease5217 (2009)a7600 (2006)bHypertension26,170 (2009)a33,000 (2009)cAnxiety and depression9815 (2009)d157,000 Lifetime (2006)Diabetes mellitus, type 23896 (2009)d7800 (2007)aChronic obstructive pulmonary disease4619 (2009)a6100 (2008)aAsthma5056 (2009)8800 (2009)Substance abuse2264 (2009)a8000 (2007)eaAdults only (≥ 18 years old).bCoronary heart disease among individuals ages ≥ 20 years old.cHypertension defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥?90 mmHg, taking antihypertensive medication or being told twice by a physician or other professional that one has hypertension.dFor individuals aged ≥ 5 years old only. Current diagnosis for 2009.ePercentage of persons ≥ 12 years old with any illicit drug use in the past month.DoD, Department of DefenseSupplementary Table 2. Full list of causes leading to death including ICD-10-CM codes, mortality rates and mortality rate ratios.Cause leading to deathICD-10-CM codeMortality rate per 1000 patient-yearsMortality rate ratio (95% CI)MS cohortNon-MS cohortCardiac/respiratory arrestI46, R09.20.0460.0202.30(0.58–9.20)Multiple sclerosisG350.9510NASuicideICD-10-CM codes for suicide are contained in the Supplementary Excel file.0.1840.0722.56 (1.26–5.16)Infections and parasitesA00–B990.8430.1356.24 (4.17–9.36)Nervous system (excluding multiple sclerosis)G00–G990.6440.1125.75 (3.66–9.04)NeoplasmsC00–D491.2881.0411.24 (0.97–1.57)Circulatory system (excluding cardiac arrest)I00–I991.6100.7612.12 (1.68–2.66)Respiratory systemJ00–J991.8550.3724.99 (3.86–6.44)Injury, poisoning and certain other consequences of external causes (excluding suicide)S00–T880.2450.1611.52 (0.87–2.68)Blood and blood-forming organs and immune disordersD50–D890.0310.0103.10 (0.52–18.55)Symptoms, signs and abnormal clinical and laboratory (excluding respiratory arrest)R00–R990.8430.1615.24 (3.56–7.70)Endocrine, nutritional and metabolic diseasesE00–E890.3070.0764.04 (2.22–7.35)Mental, behavioral and neurodevelopmental disordersF01–F990.0770.0233.35 (1.06–10.55)Eye and adnexaH00–H590.0150NADigestive systemK00–K950.2610.1651.58 (0.91–2.74)Skin and subcutaneous tissueL00–L990.0310.00310.33 (0.94–113.96)Musculoskeletal system and connective tissueM00–M990.0610.0078.71 (1.60–47.58)Genitourinary systemN00–N990.3370.0595.71 (3.06–10.65)Pregnancy, childbirth and the puerperiumO00–O9A00.007NAConditions originating in the perinatal periodP00–P96.900NACongenital malformationsQ00–Q9900NAExternal causes of morbidity (excluding suicide)V00–Y990.0310NAFactors influencing health status and contact with health servicesZ00–Z99.8900NACI, confidence interval; ICD-10-CM, International Classification of Diseases-version 10-clinical modification; MS, multiple sclerosis; NA, not applicable.Supplementary Table 3. Full list of comorbidities with procedure codes, event rates and event rate orbidityaDiagnosis and procedure codesbNumber of patients with the comorbidity, n (%)Event rate per 1000?patient-yearsCrude event rate ratio (95% CI)MS cohortNon-MS cohortMS cohortNon-MS cohortAll-cause mortalityAll-cause mortalityNA703 (4.5)1116 (1.4)10.78 (10.00–11.61)3.68 (3.46–3.90)2.93 (2.67–3.22)DepressionAll depression296.2x, 296.3x, 296.5x, 296.6x, 296.7x, 296.8x, 298.0x, 300.4x, 301.13, 308.0x, 309.0x, 309.1x, 311.xx7141 (45.5)15,459 (19.7)167.97 (164.09–171.91)59.62 (58.69–60.57)2.82 (2.74–2.90)Attempted suicideAll attempted suicideE95.0–E95.915 (0.10)29 (0.04)0.23 (0.13–0.38)0.1 (0.06–0.14)2.41 (1.29–4.49)Poisoning by solid or liquid substancesE95.00 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NAPoisoning by gases in domestic useE95.10 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NAPoisoning by other gases and vaporsE95.20 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NAHanging, strangulation and suffocationE95.30 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NASubmersion [drowning]E95.41 (0.006)0 (0.0)0.02 (0.00–0.09)0 (0.00–0.01)NAInjury by firearms, airguns and explosivesE95.50 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NAInjury by cutting and piercing instrumentE95.613 (0.08)27 (0.03)0.2 (0.11–0.34)0.09 (0.06–0.13)2.24 (1.16–4.35)Injuries by jumping from high placeE95.70 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NAInjury by other and unspecified meansE95.80 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NALate effects of self-inflicted injuryE95.91 (0.006)2 (0.003)0.02 (0.00–0.09)0.01 (0.00–0.02)2.33 (0.21–25.68)Cardiac arrhythmiasAll cardiac arrhythmias426.12, 426.13, 426.0x, 426.82, 427.41, 427.5x, 427.0x, 427.1x, 427.2x, 427.3x, 427.42, 427.6x, 427.8x, 427.9x, 785.0x, 794.314161 (26.5)11,038 (14.1)76.31 (74.00–78.66)40.0 (39.25–40.75)1.91 (1.84–1.98)Cardiac conduction disorder426.xx485 (3.1)1361 (1.7)7.57 (6.91–8.28)4.53 (4.29–4.78)1.67 (1.51–1.86)First-degree block426.1184 (0.5)241 (0.3)1.29 (1.03–1.60)0.80 (0.70–0.90)1.62 (1.27–2.08)Second-degree AV block426.12, 426.1317 (0.1)57 (0.07)0.26 (0.15–0.42)0.19 (0.14–0.24)1.39 (0.81–2.39)AV block 2:1, Mobitz I (Wenckebach block)426.1316 (0.1)44 (0.06)0.25 (0.14–0.40)0.14 (0.11–0.19)1.69 (0.96–3.00)Mobitz II426.125 (0.03)21 (0.03)0.08 (0.02–0.18)0.07 (0.04–0.11)1.11 (0.42–2.94)Third-degree AV block426.0x31 (0.2)84 (0.1)0.48 (0.32–0.68)0.28 (0.22–0.34)1.72 (1.14–2.60)QT-interval prolongation, torsades de pointes426.8227 (0.2)82 (0.1)0.41 (0.27–0.60)0.27 (0.21–0.34)1.53 (0.99–2.37)Ventricular fibrillation/flutter427.41, 427.4239 (0.2)114 (0.1)0.6 (0.43–0.82)0.38 (0.31–0.45)1.59 (1.11–2.29)Ventricular tachycardia427.1x177 (1.1)421 (0.5)2.73 (2.34–3.17)1.39 (1.26–1.53)1.96 (1.65–2.34)Cardiac arrest427.5x167 (1.1)278 (0.4)2.57 (2.19–2.98)0.92 (0.81–1.03)2.8 (2.31–3.39)Thromboembolic eventsAll thromboembolic events997.02, 430.xx, 431.xx, 432.xx, 433.xx, 434.xx, 435.xx, 436.xx, 437.xx, 438.xx, 410.xx, 411.xx, 412.xx, 413.xx, 440.xx, 441.xx, 442.1x–442.3x, 442.8x, 442.9x, 443.xx, 444.xx, 445.0x, 415.1x, 451.0x–451.2x, 451.81, 451.9x, 453.4x, 453.8x–453.9x4971 (31.7)9805 (12.5)97.84 (95.14–100.60)35.34 (34.64–36.04)2.77 (2.68–2.86)All central nervous system vascular disorders430.xx, 431.xx, 432.xx, 433.xx, 434.xx, 435.xx, 436.xx, 437.xx, 438.xx, 997.023177 (20.3)4533 (5.8)56.31 (54.37–58.31)15.52 (15.07–15.98)3.63 (3.47–3.80)Ischemic stroke433.x1, 434.x1742 (4.7)920 (1.2)11.7 (10.87–12.57)3.05 (2.86–3.25)3.83 (3.48–4.22)Hemorrhagic stroke430.xx–432.9x203 (1.3)249 (0.3)3.14 (2.72–3.60)0.82 (0.72–0.93)3.82 (3.17–4.60)Other stroke997.02, 362.3x125 (0.8)268 (0.3)1.93 (1.60–2.30)0.88 (0.78–1.00)2.18 (1.76–2.69)Transient cerebrovascular disease/ischemic attack435.xx810 (5.2)1375 (1.8)12.83 (11.97–13.75)4.58 (4.34–4.83)2.80 (2.57–3.06)Cerebrovascular disease/accident430.xx–438.xx3116 (19.9)4366 (5.6)55.04 (53.13–57.01)14.92 (14.49–15.37)3.69 (3.52–3.86)All coronary artery disorders36x.xx, 410.xx–414.xx, 440.xx–441.xx, 442.1x–442.3x, 442.8x–442.9x, 443.xx–444.xx, 445.0x, 415.1x, 451.0x–451.2x, 451.81, 451.9x, 453.4x, 453.8x–453.9x2662 (17.0)5736 (7.3)45.85 (44.13–47.63)19.83 (19.32–20.35)2.31 (2.21–2.42)Angina pectoris411.1x, 413.xx882 (5.6)2551 (3.3)14.06 (13.15–15.02)8.59 (8.26–8.93)1.64 (1.52–1.77)Acute myocardial infarction410.xx340 (2.2)741 (0.9)5.27 (4.73–5.87)2.45 (2.28–2.64)2.15 (1.89–2.44)Myocardial infarction410.xx, 412.xx623 (4.0)1436 (1.8)9.79 (9.04–10.59)4.78 (4.54–5.04)2.05 (1.86–2.25)Coronary artery embolism/thrombosis36.xx, 411.xx, 414.xx, 412.xx1717 (10.9)5347 (6.8)28.51 (27.17–29.89)18.55 (18.05–19.05)1.54 (1.46–1.62)Ischemic coronary artery disorder414.0x, 414.2x, 414.8x, 746.851477 (9.4)4694 (6.0)24.25 (23.03–25.52)16.18 (15.72–16.65)1.5 (1.41–1.59)Ischemic heart disease410.xx, 411.xx, 412.xx, 413.xx, 414.xx2045 (13.0)6159 (7.9)34.46 (32.98–35.98)21.53 (20.99–22.07)1.6 (1.52–1.68)Peripheral embolism and thrombosis444.2x80 (0.5)175 (0.2)1.23 (0.98–1.53)0.58 (0.49–0.67)2.13 (1.64–2.78)Peripheral arterial occlusive events440.xx, 441.xx, 442.1x–442.3x, 442.8x, 442.9x, 443.xx, 444.xx, 445.0x1902 (12.1)3928 (5.0)31.56 (30.16–33.01)13.37 (12.95–13.79)2.36 (2.24–2.49)Other thromboembolic events415.1x, 451.0x–451.2x, 451.81, 451.9x, 453.4x, 453.8x, 453.9x,998 (6.4)1916 (2.4)15.94 (14.97–16.97)6.41 (6.12–6.70)2.49 (2.31–2.69)Vascular hypertensive disordersAll vascular hypertensive disorders401.xx–405.xx, 437.2x, 362.11, 428.1x,7450 (47.5)27,395 (34.9)187.85 (183.61–192.16)129.53 (128.00–131.08)1.45 (1.41–1.49)Increased blood pressure/hypertension401.xx–405.xx7433 (47.4)27,354 (34.9)194.93 (190.60–199.35)134.07 (132.51–135.64)1.45 (1.42–1.49)Hypertension complications402.xx, 402.9x, 404.0x, 404.1x, 404.9x, 404.91638 (4.1)2136 (2.7)10.06 (9.29–10.87)7.17 (6.87–7.48)1.4 (1.28–1.53)Hypertensive encephalopathy437.2x31 (0.2)39 (0.05)0.48 (0.32–0.68)0.13 (0.09–0.18)3.70 (2.31–5.94)Hypertensive retinopathy362.1193 (0.6)382 (0.5)1.43 (1.15–1.75)1.26 (1.14–1.39)1.13 (0.90–1.42)Hypertensive cardiovascular disease/cardiomyopathy402.xx605 (3.9)2037 (2.6)9.53 (8.78–10.32)6.83 (6.54–7.14)1.39 (1.27–1.53)Malignant hypertension401.0x, 402.0x, 403.0x, 404.0x, 405.0x613 (3.9)1947 (2.5)9.64 (8.89–10.44)6.52 (6.23–6.82)1.48 (1.35–1.62)Hypertensive crisis437.2x, 401.0x, 405.01, 405.09569 (3.6)1769 (2.3)8.93 (8.21–9.70)5.91 (5.64–6.20)1.51 (1.37–1.66)Hypercholesterolemia/hyperlipidemiaAll hypercholesterolemia/hyperlipidemia272.0x–272.4x7554 (48.2)30,506 (38.9)188.59 (184.36–192.89)149.42 (147.75–151.11)1.26 (1.23–1.29)Pure hypercholesterolemia272.0x3168 (20.2)12,271 (15.6)56.86 (54.90–58.88)45.96 (45.15–46.78)1.24 (1.19–1.29)Hyperlipidemia272.1x–272.4x6865 (43.8)27,772 (35.4)159.83 (156.07–163.66)128.79 (127.28–130.32)1.24 (1.21–1.27)Respiratory disordersAll respiratory disorders460.xx–519.xx, 428.1x11,410 (72.7)43,344 (55.3)404.96 (397.56–412.45)256.30 (253.90–258.73)1.58 (1.55–1.61)Pulmonary edema514.xx, 518.4x503 (3.2)788 (1.0)7.84 (7.17–8.56)2.61 (2.43–2.80)3.01 (2.69–3.36)Respiratory failure (in common with bronchoconstriction/asthma)518.81, 518.82, 518.83, 518.84802 (5.1)1190 (1.5)12.58 (11.72–13.48)3.94 (3.72–4.17)3.19 (2.92–3.49)Asthma/exacerbations of asthma/status asthmaticus493.0x, 493.1x, 493.2x, 493.9x2365 (15.1)7581 (9.7)40.71 (39.08–42.38)26.91 (26.31–27.52)1.51 (1.44–1.58)Exacerbations of chronic obstructive pulmonary disease491.20, 491.21, 491.22699 (4.5)1547 (2.0)11.01 (10.21–11.86)5.16 (4.90–5.42)2.13 (1.95–2.33)Progressive multifocal leukoencephalopathyProgressive multifocal leukoencephalopathy046.3x11 (0.07)1 (0.001)0.17 (0.08–0.30)0 (0.00–0.02)51.24 (6.61–396.86)InfectionsAll infections11,596 (73.9)41,471 (52.9)425.95 (418.24–433.77)234.16 (231.91–236.42)1.82 (1.78–1.86)Respiratory infections460.xx–466.xx, 472.xx, 473.xx, 475.xx, 476.xx, 487.0x–487.8x, 488.xx, 490.xx, 491.xx9505 (60.6)36,665 (46.8)266.37 (261.04–271.78)189.08 (187.15–191.02)1.41 (1.38–1.44)Urinary tract infections590.xx, 595.xx, 599.xx6805 (43.4)17,512 (22.3)152.34 (148.74–156.00)68.26 (67.26–69.28)2.23 (2.17–2.30)Opportunistic infectionsAll opportunistic infections003.21, 007.2x, 007.4x, 010.xx–018.xx, 027.0x, 031.xx, 039.xx, 041.7x, 046.3x, 049.1x, 052.xx–054.xx, 058.xx, 078.5x, 079.6x, 079.83, 084.0x–084.6x, 084.9x, 085.xx, 111.2x, 112.4x–112.5x, 112.81, 112.83–112.85, 112.89, 114.xx–115.xx, 116.1x, 117.3x, 117.5x–117.8x, 118.xx, 130.xx, 136.3x, 321.0x, 321.1x, 321.8x, 348.8x, 363.8x, 370.8x, 466.11, 480.1x, 484.6x, 518.6x, 728.86, 729.4x, 771.2x, 771.7x, 995.903617 (23.1)6105 (7.8)64.79 (62.69–66.93)21.15 (20.62–21.68)3.06 (2.94–3.19)Adenoviral infectionsMeningoencephalitis adenoviral049.1x0 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NAAllescheria infectionsAllescheriosis117.6x0 (0.0)1 (0.001)0 (0.00–0.06)0 (0.00–0.02)NAAspergillus infectionsAll Aspergillus infections117.3x, 484.6x, 518.6x8 (0.05)30 (0.04)0.12 (0.05–0.24)0.10 (0.07–0.14)1.24 (0.57–2.71)Bronchopulmonary aspergillosis484.6x, 518.6x5 (0.03)11 (0.01)0.08 (0.02–0.18)0.04 (0.02–0.06)2.12 (0.74–6.09)Atypical mycobacterial infectionsAll atypical mycobacterial infections031.xx22 (0.1)33 (0.04)0.34 (0.21–0.51)0.11 (0.07–0.15)3.11 (1.81–5.33)Atypical mycobacterial pneumonia031.0x13 (0.08)20 (0.03)0.20 (0.11–0.34)0.07 (0.04–0.10)3.03 (1.51–6.09)Mycobacterial infection031.9x9 (0.06)13 (0.02)0.14 (0.06–0.26)0.04 (0.02–0.07)3.22 (1.38–7.54)Candida infectionsAll Candida infections112.4x, 112.5x, 112.81, 112.83, 112.84, 112.85, 112.89, 771.7x160 (1.0)282 (0.4)2.47 (2.10–2.88)0.93 (0.82–1.05)2.65 (2.18–3.22)Candida sepsis112.5x19 (0.1)33 (0.04)0.29 (0.18–0.46)0.11 (0.07–0.15)2.68 (1.52–4.72)Candida endocarditis 112.810 (0.0)4 (0.005)0 (0.00–0.06)0.01 (0.00–0.03)NACandida meningitis 112.830 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NANeonatal Candida infection771.7x0 (0.0)1 (0.001)0 (0.00–0.06)0 (0.00–0.02)NAEsophageal candidiasis112.8454 (0.3)129 (0.2)0.83 (0.62–1.08)0.43 (0.35–0.51)1.95 (1.42–2.68)Systemic Candida112.5x19 (0.1)33 (0.04)0.29 (0.18–0.46)0.11 (0.07–0.15)2.68 (1.52–4.72)Coccidioides infectionsAll Coccidioides infections114.xx13 (0.08)44 (0.06)0.20 (0.11–0.34)0.14(0.11–0.19)1.38 (0.74–2.55)Coccidioides meningitis 114.2x0 (0.0)1 (0.001)0 (0.00–0.06)0 (0.00–0.02)NACryptococcus infectionsAll Cryptococcus infections117.5x, 321.0x2 (0.01)2 (0.003)0.03 (0.00–0.11)0.01 (0.00–0.02)4.66 (0.66–33.06)Cryptococcal meningitis321.0x0 (0.0)1 (0.001)0 (0.00–0.06)0 (0.00–0.02)NACryptosporidium infectionsCryptosporidiosis007.4x2 (0.01)2 (0.003)0.03 (0.00–0.11)0.01 (0.00–0.02)4.66 (0.66–33.06)All opportunistic fungal infections118.xx2 (0.01)2 (0.003)0.03 (0.00–0.11)0.01 (0.00–0.02)4.66 (0.66–33.06)Herpes virus infectionsEncephalitis herpes058.2x, 054.3x0 (0.0)2 (0.003)0.09 (0.03–0.20)0.02 (0.01–0.04)4.66 (1.50–14.44)Herpes simplex encephalitis054.3x6 (0.04)4 (0.005)0.09 (0.03–0.20)0.01 (0.00–0.03)6.99 (1.97–24.75)All herpes virus infections052.xx, 053.xx, 054.xx, 058.xx1428 (9.1)4558 (5.8)23.2 (22.01–24.44)15.6 (15.15–16.06)1.49 (1.40–1.58)Herpes zoster053.xx724 (4.6)1903 (2.4)11.42 (10.60–12.28)6.36 (6.08–6.65)1.79 (1.65–1.95)Herpes zoster ophthalmic053.2x42 (0.3)144 (0.2)0.65 (0.46–0.87)0.47 (0.40–0.56)1.36 (0.96–1.92)Herpes zoster oticus053.713 (0.02)10 (0.01)0.05 (0.01–0.13)0.03 (0.02–0.06)1.40 (0.38–5.08)Herpes meningitis 053.0x, 054.7214 (0.09)13 (0.02)0.21 (0.12–0.36)0.04 (0.02–0.07)5.02 (2.36–10.67)Herpetic meningoencephalitis 053.1x, 053.10, 053.19111 (0.7)223 (0.3)1.71 (1.41–2.06)0.74 (0.64–0.84)2.32 (1.85–2.92)Histoplasma infectionsAll Histoplasma infections115.xx31 (0.2)73 (0.09)0.48 (0.32–0.68)0.24 (0.19–0.30)1.98 (1.30–3.01)Histoplasma endocarditis 115.04, 115.14, 115.940 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NAHistoplasma meningitis 115.01, 115.11, 115.910 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NAHistoplasma pericarditis 115.03, 115.13, 115.930 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NAHistoplasma retinitis 115.02, 115.12, 115.9221 (0.1)44 (0.06)0.32 (0.20–0.49)0.14 (0.11–0.19)2.22 (1.32–3.74)Leishmania infectionsAll Leishmania infections2 (0.01)6 (0.008)0.03 (0.00–0.11)0.02 (0.01–0.04)1.55 (0.31–7.69)Cutaneous leishmaniasis085.1x, 085.2x, 085.3x, 085.4x2 (0.01)0 (0.0)0.03 (0.00–0.11)0 (0.00–0.01)NALeishmaniasis085.xx2 (0.01)6 (0.008)0.03 (0.00–0.11)0.02 (0.01–0.04)1.55 (0.31–7.69)Mucocutaneous leishmaniasis085.5x0 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NAVisceral leishmaniasis085.0x0 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NAListeria infectionsListeriosis027.0x0 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NANocardia infectionsNocardia sepsis039.8x5 (0.03)12 (0.02)0.08 (0.02–0.18)0.04 (0.02–0.07)1.94 (0.68–5.51)Paracoccidioides infectionsParacoccidioides infection116.1x0 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NAParvoviral infectionsAll parvoviral infections0.06 (0.02–0.16)0.03 (0.01–0.05)2.33 (0.70–7.73)Erythema infectiosum079.83 and 057.0x0 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NAParvoviral infection079.834 (0.03)8 (0.01)0.06 (0.02–0.16)0.03 (0.01–0.05)2.33 (0.70–7.73)Plasmodial infectionsAll plasmodial infections084.9x084.0x, 084.1x, 084.2x, 084.3x, 084.4x, 084.5x, 084.6x6 (0.04)13 (0.02)0.09 (0.03–0.20)0.04 (0.02–0.07)2.15 (0.82–5.66)Pneumocystis infectionsAll Pneumocystis infections136.3x4 (0.03)10 (0.01)0.06 (0.02–0.16)0.03 (0.02–0.06)1.86 (0.58–5.94)Polyomavirus infectionsProgressive multifocal leukoencephalopathy046.3x11 (0.07)1 (0.001)0.17 (0.08–0.30)0 (0.00–0.02)51.24 (6.61–396.86)Respiratory syncytial virus infectionsAll respiratory syncytial virus infections26 (0.2)61 (0.08)0.4 (0.26–0.58)0.2 (0.15–0.26)1.99 (1.25–3.14)Pneumonia respiratory syncytial viral480.1x5 (0.03)6 (0.008)0.08 (0.02–0.18)0.02 (0.01–0.04)3.88 (1.18–12.72)Respiratory syncytial virus bronchiolitis466.1118 (0.1)52 (0.07)0.28 (0.16–0.44)0.17 (0.13–0.22)1.61 (0.94–2.76)Respiratory syncytial virus infection 079.6x3 (0.02)5 (0.006)0.05 (0.01–0.13)0.02 (0.01–0.04)2.79 (0.67–11.69)Salmonella infectionsSalmonella meningitis 003.210 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NAToxoplasma infectionsAll Toxoplasma infection10 (0.06)13 (0.02)0.15 (0.07–0.28)0.04 (0.02–0.07)3.58 (1.57–8.17)Toxoplasma meningitis130.0x1 (0.006)2 (0.003)0.02 (0.00–0.09)0.01 (0.00–0.02)2.33 (0.21–25.68)Toxoplasmosis130.xx10 (0.06)13 (0.02)0.15 (0.07–0.28)0.04 (0.02–0.07)3.58 (1.57–8.17)Tuberculous infectionsAll tuberculous infections175 (1.1)253 (0.3)2.70 (2.31–3.13)0.83 (0.74–0.94)3.23 (2.67–3.92)Adrenal gland tuberculosis017.6x2 (0.01)1 (0.001)0.03 (0.00–0.11)0 (0.00–0.02)9.31 (0.84–102.71)Bone tuberculosis015.xx7 (0.04)4 (0.005)0.11 (0.04–0.22)0.01 (0.00–0.03)8.15 (2.39–27.84)Tuberculous conjunctivitis 017.3x0 (0.0)1 (0.001)0 (0.00–0.06)0 (0.00–0.02)NACutaneous tuberculosis017.0x8 (0.05)12 (0.02)0.12 (0.05–0.24)0.04 (0.02–0.07)3.10 (1.27–7.60)Disseminated tuberculosis018.0x, 018.8x, 018.9x0 (0.0)3 (0.004)0 (0.00–0.06)0.01 (0.00–0.03)NATuberculous epididymitis 016.4x0 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NAExtrapulmonary tuberculosis013.xx, 014.xx, 015.xx, 016.xx, 017.xx25 (0.2)34 (0.04)0.38 (0.25–0.57)0.11 (0.08–0.16)3.43 (2.04–5.74)Female genital tract tuberculosis016.6x, 016.7x, 016.9x1 (0.006)0 (0.0)0.02 (0.00–0.09)0 (0.00–0.01)NAJoint tuberculosis015.1x, 015.2x, 015.8x, 015.9x0 (0.0)1 (0.001)0 (0.00–0.06)0 (0.00–0.02)NALupus vulgaris017.0x8 (0.05)12 (0.02)0.12 (0.05–0.24)0.04 (0.02–0.07)3.10 (1.27–7.60)Lymph node tuberculosis012.1x, 014.8x, 017.2x1 (0.006)5 (0.006)0.02 (0.00–0.09)0.02 (0.01–0.04)0.93 (0.11–7.97)Male genital tract tuberculosis016.4x, 016.5x, 016.9x0 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NATuberculous meningitis 013.0x, 013.1x1 (0.006)3 (0.004)0.02 (0.00–0.09)0.01 (0.00–0.03)1.55 (0.16–14.92)Esophageal tuberculosis017.8x0 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NAPeritoneal tuberculosis014.0x1 (0.006)0 (0.0)0.02 (0.00–0.09)0 (0.00–0.01)NATuberculous prostatitis 016.5x and 601.4x0 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NARenal tuberculosis016.0x0 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NATuberculous salpingitis 016.6x0 (0.0)0 (0.0)0.02 (0.00–0.09)0 (0.00–0.01)NASpleen tuberculosis017.7x0 (0.0)1 (0.001)0 (0.00–0.06)0 (0.00–0.02)NAThyroid tuberculosis017.5x0 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NATuberculoma of central nervous system013.2x–013.6x, 013.8x–013.9x1 (0.006)1 (0.001)0.02 (0.00–0.09)0 (0.00–0.02)4.66 (0.29–74.45)Tuberculosis010.xx–018.xx45 (0.3)148 (0.2)0.69 (0.50–0.93)0.49 (0.41–0.57)1.42 (1.02–1.98)Bladder tuberculosis 016.1x1 (0.006)1 (0.001)0.02 (0.00–0.09)0 (0.00–0.02)4.66 (0.29–74.45)Central nervous system tuberculosis 013.2x–013.6x, 013.8x–013.9x1 (0.006)1 (0.001)0.02 (0.00–0.09)0 (0.00–0.02)4.66 (0.29–74.45)Eye tuberculosis 017.3x0 (0.0)1 (0.001)0 (0.00–0.06)0 (0.00–0.02)NAGenitourinary system tuberculosis 016.xx2 (0.01)2 (0.003)0.03 (0.00–0.11)0.01 (0.00–0.02)4.66 (0.66–33.06)Intrathoracic lymph node tuberculosis012.1x0 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NAPeripheral lymph node tuberculosis 017.2x0 (0.0)1 (0.001)0 (0.00–0.06)0 (0.00–0.02)NAUreter tuberculosis 016.2x0 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NATuberculous pleurisy010.1x, 012.0x2 (0.01)2 (0.003)0.03 (0.00–0.11)0.01 (0.00–0.02)4.66 (0.66–33.06)SepsisAll sepsis995.91, 995.92797 (5.1)669 (0.9)12.52 (11.67–13.42)2.21 (2.05–2.38)5.66 (5.11–6.28)Seizures and seizure disordersAll seizure and convulsion disorders780.3x, 345.xx1937 (12.4)1525 (1.9)32.42 (30.99–33.89)5.09 (4.84–5.35)6.37 (5.96–6.81)Convulsions/seizures780.3x1555 (9.9)1204 (1.5)25.54 (24.29–26.84)4.01 (3.78–4.24)6.38 (5.91–6.87)Epilepsy (defined as multiple occurrences of seizures)345.xx1220 (7.8)963 (1.2)19.70 (18.61–20.84)3.20 (3.00–3.41)6.16 (5.66–6.70)Status epilepticus345.2x, 345.3x108 (0.7)78 (0.10)1.66 (1.36–2.01)0.26 (0.20–0.32)6.47 (4.83–8.65)MalignanciesAll malignancies140.xx–239.xx7271 (46.4)27,257 (34.8)166.85 (163.03–170.73)120.16 (118.73–121.59)1.39 (1.35–1.42)Skin neoplasms171.xx, 172.0x–172.9x, 173.0x–173.99, 176.0x, 198.2x, 232.0x–232.9x790 (5.0)2809 (3.6)12.54 (11.68–13.44)9.48 (9.13–9.84)1.32 (1.22–1.43)Melanoma172.0x–172.9x124 (0.8)348 (0.4)1.91 (1.59–2.28)1.15 (1.03–1.28)1.66 (1.35–2.04)Squamous cell carcinoma173.x20 (0.0)0 (0.0)0 (0.00–0.06)0 (0.00–0.01)NABasal cell carcinoma173.x1114 (0.7)418 (0.5)1.75 (1.44–2.10)1.38 (1.25–1.52)1.27 (1.03–1.56)Bowen's disease232.0x–232.9x122 (0.8)431 (0.5)1.88 (1.56–2.24)1.42 (1.29–1.57)1.32 (1.08–1.61)Soft-tissue sarcoma171.xx, 200.xx76 (0.5)220 (0.3)1.17 (0.92–1.46)0.73 (0.63–0.83)1.61 (1.24–2.09)Kaposi's sarcoma176.0x0 (0.0)2 (0.003)0 (0.00–0.06)0.01 (0.00–0.02)NALymphomas (one claim)200.xx–202.xx, except 202.5x and 202.6x140 (0.9)322 (0.4)2.16 (1.82–2.55)1.06 (0.95–1.19)2.03 (1.66 - 2.48)Lymphomas (two claims 60 days apart)c 200.xx–202.xx, except 202.5x and 202.6x60 (0.4)180 (0.2)0.92 (0.70–1.19)0.59 (0.51–0.69)1.55 (1.16–2.08)Non-Hodgkin's lymphomas (one claim) 202.00-202.98, 200.XX125 (0.8)310 (0.4)1.93 (1.60–2.29)1.02 (0.91–1.14)1.88 (1.53 - 2.32)Non-Hodgkin's lymphomas (two claims 60 days apart)c202.00-202.98, 200.XX54 (0.3)166 (0.2)0.83 (0.62–1.08)0.55 (0.47–0.64)1.52 (1.12–2.06)B-cell lymphoma200.3x5 (0.03)15 (0.02)0.08 (0.02–0.18)0.05 (0.03–0.08)1.55 (0.56–4.27)Burkitt's lymphoma200.2x5 (0.03)8 (0.01)0.08 (0.02–0.18)0.03 (0.01–0.05)2.91 (0.95–8.90)Primary brain lymphoma200.5x3 (0.02)3 (0.004)0.05 (0.01–0.13)0.01 (0.00–0.03)4.66 (0.94–23.07)Hodgkin's lymphoma201.00–201.9832 (0.2)64 (0.08)0.49 (0.34–0.69)0.21 (0.16–0.27)2.33 (1.52–3.56)T-cell lymphoma202.7x2 (0.01)4 (0.005)0.03 (0.00–0.11)0.01 (0.00–0.03)2.33 (0.43–12.71)Mycosis fungoides202.1x10 (0.06)15 (0.02)0.15 (0.07–0.28)0.05 (0.03–0.08)3.10 (1.39–6.91)Multiple myeloma and immunoproliferative neoplasms203.xx74 (0.5)93 (0.1)1.14 (0.89–1.43)0.31 (0.25–0.38)3.71 (2.73–5.04)Leukemia203.1x, 204.xx–205.xx, 238.72–238.7589 (0.6)207 (0.3)1.37 (1.10–1.69)0.68 (0.59–0.78)2.01 (1.56–2.57)Lymphocytic malignancy204.xx27 (0.2)84 (0.1)0.41 (0.27–0.60)0.28 (0.22–0.34)1.50 (0.97–2.31)Myeloid malignancy205.xx29 (0.2)79 (0.1)0.45 (0.30–0.64)0.26 (0.21–0.32)1.71 (1.12–2.62)Myelodysplastic syndrome238.72–238.7540 (0.3)69 (0.09)0.61 (0.44–0.84)0.23 (0.18–0.29)2.70 (1.83–3.99)Lymphoproliferative disorders (lymphomas, leukemia, multiple myeloma, except myelodysplastic syndrome)200.2x–200.7x, 201.xx–205.xx, 238.6x, 273.3x245 (1.6)516 (0.7)3.79 (3.33–4.30)1.71 (1.56–1.86)2.22 (1.91–2.59)Breast cancer174.xx, 175.xx, 198.81406 (2.6)1636 (2.1)6.36 (5.75–7.00)5.48 (5.22–5.75)1.16 (1.04–1.29)Additional cancer sitesAll additional cancer sites988 (6.3)3308 (4.2)15.8 (14.83–16.81)11.2 (10.83–11.59)1.41 (1.31–1.51)Brain and other nervous system191.xx, 192.xx82 (0.5)193 (0.2)1.26 (1.00–1.57)0.64 (0.55–0.73)1.98 (1.53–2.57)Colon and rectum153.xx, 154.0x, 154.1x, 154.4x–154.9x, 230.3x, 230.4x107 (0.7)411 (0.5)1.65 (1.35–1.99)1.36 (1.23–1.50)1.21 (0.98–1.50)Lung and bronchus162.1x–162.9x, 231.2x124 (0.8)450 (0.6)1.91 (1.59–2.28)1.49 (1.35–1.63)1.28 (1.05–1.57)Cervix uteri180.xx, 233.1x77 (0.5)279 (0.4)1.18 (0.93–1.48)0.92 (0.82–1.04)1.29 (1.00–1.65)Corpus uteri179.xx, 182.xx, 233.2x38 (0.2)189 (0.2)0.58 (0.41–0.80)0.62 (0.54–0.72)0.94 (0.66–1.33)Ovary183.xx39 (0.2)198 (0.3)0.60 (0.43–0.82)0.65 (0.57–0.75)0.92 (0.65–1.29)Stomach151xx, 230.2x25 (0.2)92 (0.1)0.38 (0.25–0.57)0.30 (0.24–0.37)1.27 (0.81–1.97)Liver155.xx, 156.xx, 230.8x31 (0.2)131 (0.2)0.48 (0.32–0.68)0.43 (0.36–0.51)1.10 (0.75–1.63)Pancreas157.xx21 (0.1)77 (0.10)0.32 (0.20–0.49)0.25 (0.20–0.32)1.27 (0.78–2.06)Kidney189.0x53 (0.3)147 (0.2)0.81 (0.61–1.07)0.48 (0.41–0.57)1.68 (1.23–2.30)Urinary/bladder188.xx48 (0.3)161 (0.2)0.74 (0.54–0.98)0.53 (0.45–0.62)1.39 (1.01–1.92)Esophagus150.xx, 230.1x12 (0.08)36 (0.05)0.18 (0.10–0.32)0.12 (0.08–0.16)1.55 (0.81–2.98)Thyroid19395 (0.6)284 (0.4)1.46 (1.18–1.79)0.94 (0.83–1.05)1.56 (1.24–1.97)All solid organ malignant neoplasms140.xx–165.xx, 170.xx–171.xx, 176.1x–176.9x, 179.xx–189.xx, 190.xx–199.xx, 209.0x–209.3x943 (6.0)3153 (4.0)15.05 (14.10–16.04)10.67 (10.30–11.05)1.41 (1.31–1.52)Leukopenia and lymphopeniaLeukopenia and lymphopenia288.5x, 288.0x626 (4.0)1305 (1.7)9.82 (9.07–10.62)4.34 (4.10–4.58)2.26 (2.06–2.49)Eye/vision disordersAll eye/vision disorders360.xx–379.xx10,571 (67.4)34,571 (44.1)339.74 (333.29–346.27)170.91 (169.12–172.72)1.99 (1.94–2.03)Macular edema362.53, 362.83, 362.07194 (1.2)477 (0.6)2.99 (2.59–3.44)1.58 (1.44–1.73)1.90 (1.61–2.24)Macular hole362.5444 (0.3)123 (0.2)0.68 (0.49–0.91)0.41 (0.34–0.48)1.67 (1.18–2.35)Hepatobiliary disordersAll hepatobiliary disorders570.xx–576.xx2388 (15.2)6856 (8.7)40.43 (38.83–42.09)23.91 (23.35–24.48)1.69 (1.61–1.77)Hepatitis/autoimmune hepatitis571.42, 571.49, 070.xx, 571.4x, 571.1x, 573.3x, 573.1x, 573.2x, 573.8x, G8545, G8461, G8463, G8549, G8458, G8460, G8462, G8869, G8870862 (5.5)2457 (3.1)13.68 (12.78–14.62)8.26 (7.93–8.59)1.66 (1.53–1.79)Hepatic encephalopathy572.2x28 (0.2)101 (0.1)0.43 (0.29–0.62)0.33 (0.27–0.40)1.29 (0.85–1.96)Jaundice782.4x75 (0.5)273 (0.3)1.15 (0.91–1.45)0.90 (0.80–1.01)1.28 (0.99–1.65)Liver transaminase elevation790.4x886 (5.6)2511 (3.2)14.09 (13.18–15.05)8.45 (8.12–8.79)1.67 (1.54–1.80)Increase in alanine aminotransferase (defined using lab values: >5.0 × upper limit of normal [ULN, >250 IU/L for males and >200 IU/L for females])9/834 (1.1)19/1687 (1.1)4.92 (2.25–9.34)5.06 (3.05–7.90)0.97 (0.44–2.15)Increase in aspartate aminotransferase (defined using lab values: >5.0 × ULN [>200 IU/L for males and >170 IU/L for females])11/824 (1.3)24/1691 (1.4)6.08 (3.04–10.89)6.41 (4.11–9.54)0.95 (0.46–1.94)Increase in γ-glutamyl transferase (defined using lab values: >5.0 × ULN [>200 IU/L])1/51 (2.0)1/68 (1.5%)9.49 (0.24–52.88)6.64 (0.17–37.02)1.43 (0.09–22.84)Renal disordersAll renal disorders580.xx–589.xx1275 (8.1)3084 (3.9)31.52 (30.12–32.97)16.59 (16.12–17.06)1.90 (1.80–2.00)Decreased renal function584.5x–584.9x, 585.5x–585.6x, 586.xx1292 (8.2)3404 (4.3)20.67 (19.56–21.83)11.48 (11.10–11.87)1.80 (1.69–1.92)Proteinuria791.0x, 593.6x343 (2.2)1286 (1.6)5.33 (4.78–5.93)4.28 (4.05–4.52)1.25 (1.11–1.40)Renal failure (acute or chronic)584.xx, 586.xx818 (5.2)1466 (1.9)12.87 (12.01–13.79)4.87 (4.63–5.13)2.64 (2.43–2.88)Hemodialysis/peritoneal dialysis (acute or chronic)996.73, 585.6x, 996.73, V41.xx, V45.11, V45.12, V45.1x, V56.0x, V56.1x, V56.2x, V56.31, V56.32, V56.8x, 36800, 36810, 36815, 36818–36821, 36825, 36830–36833, 36835, 36838, 36860, 36861, 36870, 90918–90925, 90919, 90935, 90937, 90939, 90940, 90945, 90947, 90951–90989, 90993, 90997, 90999, 99512, A4300, A4651–A4653, A4656–A4657, A4660, A4663, A4670–A4674, A4680, A4690, A4706–A4709, A4714, A4719–A4726, A4728, A4730, A4736–A4737, A4740, A4750, A4755, A4760, A4765–A4766, A4770–A4774, A4802, A4860, A4870, A4890, A4911, A4913, A4918, A4927–A4932, C1881, E1575, E1592, E1594, E15x0, E1600, E1610, E1615, E1620, E1625, E1630, E1632, E1634–E1637, E1639, E1699, G0257, G0308–G0327, G8075–G8076, G9013–G9014, S9335, S9339, 38.95, 39.27, 39.42, 39.43, 39.93, 39.94, 39.95, 54.98, 05.6xx, 0800, 0801–0804, 0809, 0820–0825, 0829–0835, 0839–0845, 0849–0855, 0859, 0880–0882, 0889?628 (4.0)1414 (1.8)9.90 (9.14–10.70)4.71 (4.47–4.96)2.10 (1.91–2.31)Autoimmune disordersAll autoimmune disorders2382 (15.2)6314 (8.1)40.66 (39.04–42.33)22.04 (21.50–22.59)1.84 (1.76–1.93)Blood Immune thrombocytopenic purpura287.3x69 (0.4)172 (0.2)1.06 (0.83–1.34)0.57 (0.49–0.66)1.87 (1.41–2.47)Autoimmune hemolytic anemia283.0x9 (0.06)25 (0.03)0.14 (0.06–0.26)0.08 (0.05–0.12)1.68 (0.78–3.59)EndocrineHashimoto's thyroiditis245.2x204 (1.3)646 (0.8)3.15 (2.74–3.62)2.14 (1.98–2.31)1.47 (1.26–1.73)Basedow–Grave disease242.0x164 (1.0)517 (0.7)2.53 (2.16–2.95)1.71 (1.57–1.86)1.48 (1.24–1.76)HepaticAutoimmune hepatitis571.4213 (0.08)30 (0.04)0.20 (0.11–0.34)0.10 (0.07–0.14)2.02 (1.05–3.87)LupusSystemic lupus erythematosus710.0x348 (2.2)575 (0.7)5.42 (4.87–6.02)1.9 (1.75–2.07)2.85 (2.49–3.25)Cutaneous lupus erythematosus695.4x98 (0.6)217 (0.3)1.51 (1.22–1.84)0.72 (0.62–0.82)2.11 (1.66–2.67)OtherRheumatoid arthritis714.xx743 (4.7)1989 (2.5)11.78 (10.94–12.65)6.67 (6.38–6.97)1.76 (1.62–1.92)Scleroderma710.1x, 701.0x, 701.1x497 (3.2)1483 (1.9)7.77 (7.10–8.48)4.94 (4.70–5.20)1.57 (1.42–1.74)Sarcoidosis135.xx128 (0.8)243 (0.3)1.97 (1.65–2.35)0.80 (0.7–0.91)2.46 (1.99–3.05)Guillain–Barré syndrome357.0x38 (0.2)39 (0.05)0.58 (0.41–0.80)0.13 (0.09–0.18)4.54 (2.91–7.10)Sj?gren's syndrome710.2x229 (1.5)372 (0.5)3.55 (3.10–4.04)1.23 (1.11–1.36)2.88 (2.45–3.40)Vasculitis136.1x, 287.0x, 443.1x, 446.xx, 447.6x, 695.89, 701.8x, 709.1x545 (3.5)1373 (1.8)8.53 (7.83–9.28)4.57 (4.33–4.82)1.87 (1.69–2.06)DiabetesDiabetes mellitus250.xx2836 (18.1)10,199 (13.0)50.46 (48.62–52.36)37.68 (36.95–38.41)1.34 (1.28–1.40)PsoriasisAll psoriasis696.0x, 696.1x, 696.2x366 (2.3)1256 (1.6)5.71 (5.14–6.33)4.19 (3.96–4.42)1.36 (1.21–1.53)Regional enteritis including Crohn's diseaseAll regional enteritis including Crohn's disease555.xx156 (1.0)376 (0.5)2.41 (2.05–2.82)1.24 (1.12–1.37)1.94 (1.61–2.34)Ulcerative colitisAll ulcerative colitis556.xx210 (1.3)496 (0.6)3.25 (2.82–3.72)1.64 (1.50–1.79)1.98 (1.69–2.33)Disorders of thyroid glandAll disorders of thyroid gland240.xx–242.xx, 244.xx–246.xx, 226.xx, 648.1x, 017.5x, 376.2x, 874.2x, 874.3x, 122.2x, 794.5x4063 (25.9)13,344 (17.0)77.31 (74.95–79.72)50.80 (49.95–51.67)1.52 (1.47–1.58)Hemophagocytic lymphohistiocytosisAll hemophagocytic lymphohistocytosis288.4x0 (0.0)5 (0.006)0 (0.00–0.06)0.02 (0.01–0.04)NAUveitisAll uveitis017.3x, 053.22, 054.44, 091.5x, 098.41, 130.2x, 360.11, 360.12, 363.20, 363.21, 364.0x–364.3x268 (1.7)524 (0.7)4.16 (3.68–4.69)1.73 (1.59–1.89)2.40 (2.07–2.78)Other topics/endpointsAll other topics/endpoints202 (1.3)709 (0.9)3.12 (2.71–3.59)2.35 (2.18–2.53)1.33 (1.14–1.55)Percutaneous transluminal coronary angioplasty00.66, 17.55, 92982, 92984, 92995, 92996123 (0.8)410 (0.5)1.90 (1.58–2.26)1.36 (1.23–1.49)1.40 (1.14–1.71)Percutaneous transluminal coronary stent36.06, 36.07, G0290, G0291, 92980, 92981166 (1.1)539 (0.7)2.56 (2.19–2.98)1.79 (1.65–1.95)1.43 (1.20–1.70)Coronary artery bypass graft36.10–36.17, 36.19, S2205–S2209, 33510–33514, 33516–33519, 33521–33523, 33530, 33533–3353638 (0.2)183 (0.2)0.58 (0.41–0.80)0.60 (0.52–0.70)0.97 (0.68–1.37)aThere were no specific codes for bacterial infections NEC, cytomegaloviral infections, fungal infections NEC, Isospora infections and Pseudallescheria infections. It was therefore not possible to assess event rates and event rate ratios for these comorbidities. bDiagnosis and procedure codes include the following: International classification of diseases-version 9-clinical modification (ICD-9-CM) codes, Healthcare Common Procedure Coding System (HCPCS) and Current Procedural Terminology (CPT).cA sensitivity analysis performed based on recent meta-analysis publication. ADDIN EN.CITE <EndNote><Cite><Author>Herman</Author><Year>2012</Year><RecNum>182</RecNum><DisplayText>(Herman et al. , 2012)</DisplayText><record><rec-number>182</rec-number><foreign-keys><key app="EN" db-id="dxa9p0dzrxszx0epfaw52s5j29pffrf9e20s">182</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Herman, R. A.</author><author>Gilchrist, B.</author><author>Link, B. K.</author><author>Carnahan, R.</author></authors></contributors><auth-address>Division of Drug Information Services, The University of Iowa College of Pharmacy, Iowa City, IA 52242-4710, USA. Ronald-A-Herman@uiowa.edu.</auth-address><titles><title>A systematic review of validated methods for identifying lymphoma using administrative data</title><secondary-title>Pharmacoepidemiol Drug Saf</secondary-title></titles><pages>203–12</pages><volume>21 Suppl 1</volume><edition>2012/01/25</edition><keywords><keyword>*Algorithms</keyword><keyword>Canada/epidemiology</keyword><keyword>Databases, Factual/*statistics &amp; numerical data</keyword><keyword>Humans</keyword><keyword>Lymphoma/diagnosis/*epidemiology</keyword><keyword>Outcome Assessment (Health Care)</keyword><keyword>Predictive Value of Tests</keyword><keyword>Registries</keyword><keyword>Sensitivity and Specificity</keyword><keyword>United States/epidemiology</keyword><keyword>*Validation Studies as Topic</keyword></keywords><dates><year>2012</year><pub-dates><date>Jan</date></pub-dates></dates><isbn>1099-1557 (Electronic)&#xD;1053-8569 (Linking)</isbn><accession-num>22262607</accession-num><urls><related-urls><url>;(Herman et al. , 2012)AV, atrioventricular; CI, confidence interval; CPT, Current Procedural Terminology; HCPCS, Healthcare Common Procedure Coding System; ICD-9-CM, International Classification of Diseases-version 9-clinical modification; MS, multiple sclerosis; NA, not applicable; NEC, necrotizing enterocolitis; ULN, upper limit of normal.ReferenceHerman RA, Gilchrist B, Link BK, Carnahan R. A systematic review of validated methods for identifying lymphoma using administrative data. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:203–12. ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download